XXXX Welcome everyone. the afternoon first conference good and to Kim you, call. quarter Thank
White, and you and our the Strategy Board CEO and President and Cooper spend Cooper Before while Companies, on this I on with Directors. Cooper to CEO the of XX fantastic the a earlier of new become at And Company family, Chief plus, Company it's as I CooperSurgical, calendar Al April more get year Holding XX to getting CEO, The years today, time will retire into him through the traveling transitioning the role CEO at CFO, who as know May little golf. time President as Medical years effective end with quarter, Officer, plus announced work the of will we remaining of trying a as most year. of -- will better with my me and Xst. the After last for along XX
would of many time XX lot I last planning I say time on years. the from been we this such know, the highly the when that confidence As leader step My to to the description for bench of has goal down, is that you the fits be within. prepare executive to spent able and right of a came over I'm train deep to working trained future Al Companies. happy leadership and promote that have a Cooper complete succession he
through completed low of company expanded team the and recently we proud States had the largest CooperSurgical, only United material CooperVision, help the saw passion the acquisitions industry our of accomplishments I've years, to little called XX medical all I and the modalities PARAGARD leading on past a -- several Sauflon three that a the company. hydrogel hydrogel best one-day with there of a our all from acquired and At us building and device Over a around employees. world. acquisition. the Origio in map with -- we Paragon the the silicone player offerings of privilege new am acquisition our the our And IVF to we a grow became products. trade-up our and company silicone continue put cost outside of family of globally the in called as acquisition At the great of
to XX-plus thank want and years. performance. work fantastic hard their me a for turn and to dedication let them for I With So, that,
$XXX forma. as $XXX quarter, Biofinity up share posted XX% year-over-year, posted up forma. up $X.XX, revenues in non-GAAP year-over-year. combined down X% the XX% and of reported, revenues revenues, we Avaira CooperVision forma, up hydrogel For up QX million XX% per reported of $XXX of did pro million, XX% earnings drove as X% X% consolidated forma. pro lenses pro and as growth Daily up million, pro XX% reported, CooperSurgical up silicone
with pro EMEA, solid details. quarter to This up up up the X%; X%; Moving in all all the and was growth Americas forma. a for including regions, Asia-Pacific, CooperVision XX%,
the As single-digits. in a was Americas in low expected, growth
stronger we that and QX However, the the expect be of in to remainder year.
Regarding EMEA had Asia-Pac, good quarters. and very both
regions. by in the our space in driven monthly to gaining hydrogel share and Clariti our both Overall, continue revenues in be MyDay silicone continue and Biofinity by space. all we in dailies So, led -- lenses, the
of are help geographically, feedback our MyDay States. been believe while further also the in offerings of MyDay United to adoption helping expand one-day growth launch will accelerate We the has including launch and Toric positive, here. drive continuing the very Toric The we
well. also extremely Our perform products one-day to Clariti continue
to products. Moving other
and to perform our Biofinity Our grow transitioning to slightly growth the where Vitality anticipate Avaira upgraded Avaira pro lenses, well diversified of forma. world. continue by of Biofinity as end family combined X% around declined focus our to Avaira the which with on lenses this we completing year. very remained
X% leader by remain grew driven We MyDay, categories. Toric, product Clariti. forma, Biofinity, to global pro in and Turning which
than grew portfolio in the to with and share U.S. from that strength Multifocals will X% the believe Biofinity forma and addition given coming in the growth recent overall Toric market and MyDay grow that of we our market, continue Clariti. faster pro We will Toric strong
Turning to soft contact market the -- global market. lens
up growing with Asia-Pac, up while XX% a up X% basis, -- in market the X% up of X%. lenses market with the continue market market versus for for X% up X% EMEA, up comp market. XX% year For market CooperVision's a the X%; and the up X% taking up X% X%. XX% X%. finally, CooperVision modality, market single-use share grew X%. very lenses market, versus On faster the versus QX, on XX% versus By Americas we calendar And grew This included up grew market versus Americas declined come X% difficult we CooperVision grew the the XX%. non-single-use than calendar The the the
Going continue forward, and to growing X% to market. the we X% still faster than market growth targeting we are expect
to hitting with a of basis, forma Moving expected declines due an all-time of we XX% by growth pro On reported last with revenues quarter. declined million, high mostly acquisition X%, CooperSurgical, we year-over-year PARAGARD. PARAGARD, revenue driven discussed $XXX to the up our of which we
we levels a now demand. QX, As was Further built on so there market acquired future we reps November our the no normal to channel and sales supporting XXXX from We acquisition. significant prior closely end for year as on which the direct follow the after may Xst, salesforce PARAGARD, recall PARAGARD to XX our conversations of was soon inherited or purchased new reminder, reps the one hiring roughly and sales began this return approximately during Inventory it. direct should month. we by more acquisition have you growth inventory, discussions, product will prior before
this, expect our fiscal a quarter of impact see Given to full third positive we quarter. beginning in
be as IUD we do on the we remain the to form and only product's non-hormonal U.S. communicate we birth or the very will reversible it So, well long-acting continue well positive market benefits. will PARAGARD. believe control on It's we -- overall,
Excluding with PARAGARD, business grew surgical our X% office and in expectations. line
our medical our which continued devices, declined earnings XX%. until testing but the testing of entered part regarding includes solutions on year and genetics fertility like up median the business, margins. products X%, performing years discussed several well business experiencing genetic well competitive as business pricing call and performing We fertility, last was last a our market ago really we significant began Regarding pressure
our we part know focus unprofitable of an and models, which it process said the plan fertility businesses meant fertility solutions. rather ties to allowing Having genetic testing that, remain has matching exit genetic process highly important we as participant to you sustainable As a some business on remains than -- pricing. to
running our this operation, fertility our will well-managed end remain continue year. of likely on results in Given will through testing on our to genetic the focus drag category a
and fertility it will drive hard turn continue I In employees perform side, dedication. portfolio express market over positive results. continue I'll And to Al. combined the the positive trends with work want and to On believe our to to appreciation our solutions for product with our that, my well to we conclusion, their